Moreover, FTO showed an oncogenic role in HIF2αlow/− ccRCC by stabilizing the mRNA of BRD9. Inhibition of BRD9 in BALB/c mice bearing HIF2αlow/− ccRCC cell line–derived xenografts and patient-derived tumor xenografts led to tumor growth inhibition and prolonged survival with greater efficacy than sunitinib [105]. The gene discussed is BRD9; the disease is nonpapillary renal cell carcinoma.